Get the Stockscreener App
2.03
0.00%
0.00
After Hours:
2.03
Omniab Inc stock is traded at $2.03, with a volume of 285.80K.
It is up +0.00% in the last 24 hours and down -19.44% over the past month.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
See More
Previous Close:
$2.03
Open:
$2.06
24h Volume:
285.80K
Relative Volume:
0.41
Market Cap:
$294.29M
Revenue:
$28.94M
Net Income/Loss:
$-54.29M
P/E Ratio:
-4.3684
EPS:
-0.4647
Net Cash Flow:
$-26.02M
1W Performance:
-2.40%
1M Performance:
-19.44%
6M Performance:
+3.57%
1Y Performance:
-3.33%
1-Day Range:
$2.015
$2.13
1-Week Range:
$2.005
$2.15
52-Week Range:
$1.30
$2.79
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
2.03 | 294.29M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - Benzinga
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
OABI|OmniAb Inc|Price:2.000|Chg%:-0.030 - TradingKey
Veraxa advances cancer therapy program with OmniAb - Investing.com
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com Canada
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan
OmniAb Inc (OABI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OmniAb Inc (OABI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
OmniAb Inc (OABI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OmniAb Market Sentiment - Benzinga
Price to sales forward of OmniAb, Inc. – NASDAQ:OABI - TradingView
OmniAb Inc (OABI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OmniAb (OABI) Holds Near Support Amid Modest DeclineFear Greed Extreme - dars.gov.et
OmniAb spotlights OmniUltra platform for radioligand therapy at San Diego summit - Traders Union
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OABI|OmniAb Inc|Price:2.030|Chg%:-0.010 - TradingKey
OmniAb to present in vivo discovery technology for radioligand therapy at San Diego summit - Traders Union
Enterprise value to EBITDA forward of OmniAb, Inc. – NASDAQ:OABI - TradingView
OmniAb Q1 2026 Earnings: EPS Surprises Positively Despite Pre-Revenue StageAnalyst Earnings Estimate - dars.gov.et
OmniAb to Report Second Quarter 2026 Financial Results on August 6 - BioSpace
OmniAb stock rises after naming new chief operating officer - Investing.com
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer Effective July 13, 2026 - geneonline.com
OmniAb, Inc. Appoints Amechi Nwachuku as Chief Operating Officer – Leadership Update July 2026 - Minichart
OmniAb appoints Amechi Nwachuku as chief operating officer - Investing.com UK
OMEGA relocates headquarters from Cambridge to New Philadelphia - AOL.com
Omniab, Inc. Appoints Amechi Nwachuku as Executive Vice President and Chief Operating Officer, Effective July 13, 2026 - marketscreener.com
OmniAb Taps Amechi Nwachuku as Executive Vice President & Chief Operating Officer - Contract Pharma
OmniAb stock rises after naming new chief operating officer By Investing.com - Investing.com Nigeria
OmniAb Appoints Amechi Nwachuku COO to Expand xPloration Platform Commercialization - citybiz
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer - Moomoo
OmniAb appoints Amechi Nwachuku as chief operating officer By Investing.com - Investing.com South Africa
OmniAb Names Amechi Nwachuku Chief Operating Officer - TipRanks
Amechi Nwachuku named COO at OmniAb with stock options and severance - TradingView
OmniAb (NASDAQ: OABI) hires COO with $445K salary, 800K options - Stock Titan
OmniAb Inc. (OABI) Climbs 2.23% as Shares Approach Key Resistance at $2.40Strangle Setup - dars.gov.et
OmniAb (OABI) Edges Lower Amid Quiet Trading – Support Levels in FocusLow Volume Node - dars.gov.et
OABI,VKTX Revenue Breakdown - Finviz
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - GlobeNewswire Inc.
OmniAb Inc. (OABI) Edges Higher, Testing Key Resistance ZoneMomentum Breakout Ideas - dars.gov.et
OmniAb (OABI) Price Target Decreased by 13.73% to 7.48 - MSN
OABIOmniAb Inc Volatility & Greeks - Finviz
OmniAb (OABI) Gains More Than 38% Over 6 Months, Can It Go Higher? - Yahoo Finance
OmniAb, Inc. Warrant 2022- on Omniab Inc Financial Disclosures & SEC Filings - TradingView
OmniAb, Inc. Financial Disclosures & SEC Filings - TradingView
OmniAb (NASDAQ:OABI) Cash Burn Looks Manageable - Kalkine Media
OmniAb, Inc.(NasdaqGM: OABI) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):